Euroz Hartleys Report | 25 October 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.

Click here to view the report.

Vince Ippolito speaks with Proactive

/in , /by

Botanix President and Executive Chairman, Vince Ippolito, was interviewed by Christine Corrado from Proactive’s New York studio yesterday.

Their conversation focused on the recent launch of our BTX 1204A canine study for atopic dermatitis and our BTX 1702 rosacea study in Australia and New Zealand.

In commenting on the potential for the atopic dermatitis study, Vince said:

“A successful outcome for this study could lead to partnering opportunities for Botanix in animal health … a $750m dollar market. As well as back into another Phase2b study in humans for atopic dermatitis.”

Take a look:

Euroz Hartleys Report | 29 September 2021

/in , , /by

Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.

Click here to view the report.

Dermatology Update

/in , /by

Botanix Pharmaceuticals (ASX:BOT) has today provided an update on its dermatology program, focusing on the BTX 1204A canine study for atopic dermatitis and BTX 1702 rosacea study.

The BTX 1204A canine study for atopic dermatitis has now been launched. This will enrol 45 canines and evaluate two formulations of BTX 1204A. Positive data from a pilot study in May has already demonstrated that a new higher dose of synthetic CBD, in a novel Permetrex™ formulation, reduces severity of atopic dermatitis over 28 days – providing strong foundations to extend this program into both animal and human health.

The BTX 1702 rosacea study is also gaining momentum. Despite COVID-19 restrictions, recruitment is progressing according to plan in Australia and New Zealand – with a goal to enrol 120 patients to investigate the safety and tolerability of two different concentrations of BTX1702.

Click here to read today’s ASX Release

Botanix Expands Management Team

/in , /by

Botanix (ASX:BOT) has expanded its management team with the appointment of new Senior Vice President of Pharmaceutical Development, Dr Jack Hoblitzell.

Dr Hoblitzell brings over 30 years of extensive experience in leading world-class technical operations, manufacturing and supply chain management. He has held senior leadership roles in the US with companies including Pfizer, King Pharmaceuticals, Ivax Pharmaceuticals and Teva Pharmaceuticals, where he led numerous successful new product launches and regulatory submissions.

Vince Ippolito, President and Executive Chairman, commented:

“We are pleased to welcome Jack to the Botanix team. His depth of experience and success in leading successful new product launches and regulatory submissions will be invaluable as we continue to focus on our clinical programs as they move into last stage studies and commercial manufacturing, as well as our increasing work with the Permetrex™ platform.”

Click here to read today’s ASX release.

4th International Cannabinoid Derived Pharmaceuticals Summit

/in , , /by

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

Corporate Update Presentation

/in , , /by

Botanix Pharmaceuticals has released a corporate presentation to the ASX this morning, which is being shared with investors as part of meetings over the course of the next week.

Key highlights include:

  • Successful launch of BTX 1702 rosacea clinical study, with recruitment well underway
  • Design of the BTX 1204A pilot study of canines with atopic dermatitis, which is about to commence 
  • Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients
  • Reviewing new opportunities to leverage the unique properties of our Permetrex™ technology platform in dermatology 

Our Company remains in a strong financial position, holding a cash balance of A$21.56m at 30 June 2021, and is progressing strategically forward to deliver these core programs.

Read Presentation and ASX Release here.

Botanix FY21 Annual Report

/in , /by

Botanix (ASX:BOT) has today published its its Annual Report for the 2020-2021 Financial Year (FY21)

Key highlights from this financial year include:

  • Successful completion of BTX 1801 antimicrobial  Phase 2a  clinical  study, showing two different BTX 1801 formulations were safe, well tolerated and successful at eradicating Staphylococcus Aureus.
  • BTX 1702 rosacea clinical study was successfully launched in Australia & New Zealand and is actively recruiting.
  • Positive results achieved from the BTX 1204A pilot study of canines with atopic dermatitis, with a larger proof of concept canine study ready to kick off.
  • Expansion of the Management team  in  the  US  to  drive  clinical  and  commercial activities across the antimicrobial and dermatology programs.
  • Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients is progressing well and is positioned to validate synthetic CBD as a novel new antimicrobial.

Click here to read the report.

Research Report by Euroz Hartleys

/in , /by

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has initiated coverage on Botanix as we lead into an exciting 12 months of clinical studies and corporate activities.

This report reinforces our belief that Botanix has assembled the right people, technology and research strategies to advance our assets, and to deliver positive results for our shareholders and the patients we exist to serve.

Read the full report.

/in , , /by

Botanix (ASX:BOT) is pleased to share leading stockbroking firm, Euroz Hartleys has initiated coverage of Botanix, with the release of a comprehensive 56-page initial report.

Click here to view the report.